Loading...
Please wait, while we are loading the content...
Similar Documents
Compounds, Compositions, and Methods for The Treatment of Cancers
| Content Provider | The Lens |
|---|---|
| Abstract | The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one carboxylate or carbamate ligand. |
| Related Links | https://www.lens.org/lens/patent/012-771-160-063-520/frontpage |
| Language | English |
| Publisher Date | 2017-03-30 |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Patent |
| Jurisdiction | United States of America |
| Date Applied | 2016-12-13 |
| Applicant | Placon Therapeutics Inc |
| Application No. | 201615377857 |
| Claim | A method of inhibiting proliferation of a cell comprising contacting the cell with an effective amount of a compound of selected from the group consisting of The method of claim 1 , wherein the cell is a cancer cel The method of claim 2 , wherein the cancer cell is selected from the group consisting of a lung cancer cell, a breast cancer cell, a colorectal cancer cell, an ovarian cancer cell, a bladder cancer cell, a prostate cancer cell, a cervical cancer cell, a renal cancer cell, a leukemia cell, a central nervous system cancer cell, a myeloma cell, and a melanoma cel The method of claim 2 , wherein the compound induces cell death of the cancer cel The method of claim 1 , wherein the platinum level in the cell is increased. The method of claim 1 , wherein the compound is dosed as a nanoparticle. The method of claim 6 , wherein the nanoparticle comprises polyester. The method of claim 7 , where the polyester is selected from polycaprolactone, poly(p-dioxanone), poly(butylene succinate), polycarbonate, polylactide, polyglycolide, or poly(lactide-co-glycolide). The method of claim 8 , wherein the polyester is selected from polylactide, polyglycolide, or poly(lactide-co-glycolide). The method of claim 9 , wherein the polylactide, polyglycolide, or poly(lactide-co-glycolide) has a number weight molecular weight of about 15 kDa to about 200 kDa. The method of claim 6 , wherein the nanoparticle comprises a PEGylated polylactide, a PEGylated polyglycolide, or a PEGylated poly(lactide-co-polyglycolide. The method of claim 11 , wherein the PEG unit in the PEGylated polylactide, PEGylated polyglycolide, or PEGylated poly(lactide-co-polyglycolide has a number average molecular weight from about 1 kDa to 25 kDa. The method of claim 6 , wherein the nanoparticle has an average particle size between about 20 nm and about 220 nm. The method of claim 6 , wherein the nanoparticle is formulated in sucrose. The method of claim 6 , wherein less than 50% of the compound is released in the first hour. The method of claim 6 , wherein the compound is released in the course of 48 hours. The method of claim 1 , wherein the compound is dosed as a free compound. The method of claim 15 , wherein the free compound is formulated with a surfactant. The method of claim 15 , wherein the free compound is formulated with a lyoprotectant. The method of claim 15 , wherein the free compound is formulated with Solutol®, sucrose, or physiological saline. A method of treating cancer in a subject, the method comprising administering to the subject an effective amount of a compound of a compound of selected from the group consisting of The method of claim 21 , wherein the cancer is selected from the group consisting of lung cancer, breast cancer, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, cervical cancer, renal cancer, leukemia, central nervous system cancers, myeloma, and melanoma. |
| CPC Classification | Preparations For Medical; Dental Or Toiletry Purposes Specific Therapeutic Activity Of Chemical Compounds Or Medicinal Preparations ACYCLIC; CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON; HYDROGEN; HALOGEN; OXYGEN; NITROGEN; SULFUR; SELENIUM OR TELLURIUM TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION |
| Extended Family | 012-771-160-063-520 056-025-282-104-070 097-620-441-425-335 095-157-389-975-756 038-708-102-752-805 144-158-631-436-217 |
| Patent ID | 20170087118 |
| Inventor/Author | Bilodeau Mark T Dunbar Craig A Barder Timothy E Lee Edward R Alargova Rossitza G Rockwood Danielle N Shinde Rajesh Lim Soo Patrick Moreau Benoît |
| IPC | A61K31/282 A61K9/00 A61K9/08 A61K47/26 A61K47/34 |
| Status | Active |
| Owner | Placon Therapeutics Inc Xlink Therapeutics Inc Blend Therapeutics Inc |
| Simple Family | 012-771-160-063-520 095-157-389-975-756 097-620-441-425-335 056-025-282-104-070 038-708-102-752-805 144-158-631-436-217 |
| CPC (with Group) | A61K31/282 A61P35/00 C07F15/0093 Y10T428/298 A61K9/0019 A61K9/08 A61K9/5153 A61K47/26 A61K47/34 |
| Issuing Authority | United States Patent and Trademark Office (USPTO) |
| Kind | Patent Application Publication |
